Low frequency mutation of the Ephrin receptor A3 gene in hepatocellular carcinoma

Neoplasma

Volumn 56, Issue 4, 2009, Pages 331-334

  Bae, H J ^a   Song, J H ^a   Noh, J H ^a   Kim, J K ^a   Jung, K H ^a   Eun, J W ^a   Xie, H J ^a   Ryu, J C ^b   Ahn, Y M ^c   Kim, S Y ^a   Lee, S H ^a   Yoo, N J ^a   Lee, J Y ^a   Park, W S ^a   Nam, S W ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Eph receptor; EphA3; Hepatocellular carcinoma; Mutation

Indexed keywords

EPHRIN RECEPTOR A3; EPHA3 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; CANCER STAGING; DISEASE COURSE; GENETICS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 68149142724     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_04_331     Document Type: Article

References (23)

1. Villanueva A, Newell P, Chiang DY et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007; 27: 55-76. doi:10.1055/s-2006-960171
2. Song J, Kim CJ, Cho YG et al. Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J Gastroenterol Hepatol. 2006; 21: 1286-1289 doi:10.1111/j.1440- 1746.2006.04445.x
3. Satoh S, Daigo Y, Furukawa Y et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24: 245-250 doi:10.1038/73448
4. de La Coste A, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1998; 95: 8847-8851 doi:10.1073/pnas.95.15.8847
5. Pang A, Ng IO, Fan ST, Kwong YL. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet. 2003; 146: 8-15. doi:10.1016/S0165- 4608(03)00103-111
6. Heroult M, Schaffner F, Augustin HG. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res. 2006; 312: 642-650 doi:10.1016/ j.yexcr.2005.10.028
7. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004; 15: 419-433 doi:10.1016/j.cytogfr. 2004.09.002
8. A Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene. 2000; 19: 5614-5619 doi:10.1038/sj.onc.1203856
9. Stephens P, Edkins S, Davies H et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005; 37: 590-592 doi:10.1038/ng1571
10. Davies H, Hunter C, Smith R et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65: 7591-7595
11. Balakrishnan A, Bleeker FE, Lamba S et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res. 2007; 67: 3545-3550 doi:10.1158/0008-5472.CAN-07-0065
12. Bardelli A, Parsons DW, Silliman N et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003; 300: 949. doi:10.1126/science.1082596
13. Wood LD, Calhoun ES, Silliman N et al. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat. 2006; 27: 1060-1061 doi:10.1002/humu.9452
14. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene. 2006; 25: 3801-3809 doi:10.1038/ sj.onc.1209561
15. Nam SW, Park JY, Ramasamy A et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology. 2005; 42: 809-818 doi:10.1002/hep.20878
16. Pejovic T. Genetic changes in ovarian cancer. Ann Med. 1995; 27: 73-78 doi:10.3109/07853899509031940
17. Holder N, Klein R. Eph receptors and ephrins: effectors of morphogenesis. Development. 1999; 126: 2033-2044
18. Sharfe N, Freywald A, Toro A, Roifman CM. Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells. J Immunol. 2003; 170: 6024-6032
19. Smith LM, Walsh PT, Rudiger T et al. EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion. Exp Cell Res. 2004; 292: 295-303. doi:10.1016/j.yexcr.2003.08.021
20. Lawrenson ID, Wimmer-Kleikamp SH, Lock P et al. Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci. 2002; 115: 1059-1072
21. Hafner C, Schmitz G, Meyer S et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem. 2004; 50: 490-499 doi:10.1373/clinchem. 2003.026849
22. Dobrzanski P, Hunter K, Jones-Bolin S et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 2004; 64: 910-919 doi:10.1158/0008-5472.CAN-3430-2
23. Smith FM, Vearing C, Lackmann M et al. Dissecting the EphA3/Ephrin - A5 interactions using a novel functional mutagenesis screen. J Biol Chem. 2004; 279: 9522-9531 doi:10.1074/jbc.M309326200 PMid:14660665